Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Linen co-ords AbbVie's venetoclax combined with azacitidine significantly prolongs OS in first-line AML treatment Four domestically produced new anti-tumo ...

7-10 in San Diego. Trial finds AML drug is safe in healthy volunteers A randomized Phase 1 trial in healthy volunteers found a new drug targeting treatment-resistant acute myeloid leukemia (AML ...

The drug, a selective CDK9 inhibitor, is being studied for its effectiveness in treating patients with relapsed or refractory acute myeloid leukemia (r/r AML). The latest results from the trial ...

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...

California-based Apollomics had been testing uproleselan as an adjunct to chemotherapy in relapsed and refractory acute ...

Exicure joins hands with GPCR Therapeutics for growth in biotech: Chicago Saturday, December 28, 2024, 14:00 Hrs [IST] Exicure, Inc., an early-stage biotechnology company, has ann ...

DelveInsight's“Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted ...

The drug, a selective CDK9 inhibitor, is being studied for its effectiveness in treating patients with relapsed or refractory acute myeloid leukemia (r/r AML). The latest results from the trial ...